The Essential Role of Real World Evidence Combating COVID-19
Are you prepared for potential accelerated approval requirements?
Keeping a Focus on Rare Disease During COVID-19
In this time of a viral pandemic, it is still important to keep a focus on rare diseases.
ISPE’s Position on Real World Evidence (RWE)
Read more about the February 2020 position on RWE from ISPE.
Lack of Label Alignment & Patient Safety Implications
Read the full article from UBC’s pharmacovigilance team in Drugs Real World Outcomes.
Risk Management Plan Development & Implementation
Listen to the full podcast from UBC with PharmaVOICE here.
Are You Ready For Sentinel? | New RWE Safety Initiative
With continued investment in the RWE space, find out how to meet the needs of regulators, payers, and prescribers.
Immunogenicity: Meeting the Safety Reporting Requirements
Discover why it is imperative to assess the potential of therapeutic proteins throughout the product lifecycle.
DIA 2019: Watch the Wrap-up of UBC’s Participation
See more of the developments UBC’s evidence development and safety & risk management teams discussed.
OCT East Recap: RWD Trends in Clinical Studies
This prominent clinical trial event discussed the future of real-world evidence and it’s importance.
NIH Rare Disease Day: Research Brings Hope
Read the full takeaways from the 2018 Rare Disease Day hosted by the NIH.
